Filing Details
- Accession Number:
- 0001567619-20-015711
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-18 17:09:58
- Reporting Period:
- 2020-08-14
- Accepted Time:
- 2020-08-18 17:09:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1800619 | Nimrata Hunt | Idexx Laboratories, Inc. One Idexx Drive Westbrook ME 04092 | Executive Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2020-08-14 | 2,676 | $377.50 | 7,947 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2020-08-14 | 100 | $377.51 | 7,847 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2020-08-18 | 698 | $79.54 | 8,545 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2020-08-18 | 1,107 | $67.85 | 9,652 | No | 4 | M | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Incentive Stock Option (right-to-buy) | Disposition | 2020-08-18 | 698 | $0.00 | 698 | $79.54 |
| Common Stock | Incentive Stock Option (right-to-buy) | Disposition | 2020-08-18 | 1,107 | $0.00 | 1,107 | $67.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2025-02-13 | No | 4 | M | Direct | |
| 769 | 2026-02-13 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 160 | Indirect | jointly with spouse |
Footnotes
- Includes a total of 38 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on March 31, 2020 and June 30, 2020.
- Grant of option to buy 1,366 shares of Issuer common stock that vests in five annual installments beginning on February 14, 2016. The number of derivative securities reported as beneficially owned and price with respect to this option were adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015.
- Grant of option to buy 1,906 shares of Issuer common stock that vests as to 1 share on February 14, 2017, 29 shares on February 14, 2018, 365 shares on February 14, 2019, 742 shares on February 14, 2020 and as to the remainder on February 14, 2021.
- Not applicable.
Billionaire Hedge Funds
